SENORES PHARMS
GenericsSENORES PHARMS is a generic drug manufacturer focused on Cardiovascular, Immunology, Neurology.
SENORES PHARMS's Key Drugs
SENORES PHARMS's core commercial portfolio centers on PRASUGREL, CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, spanning Cardiovascular and Immunology — its most strategically important drugs approved in the last 15 years.
SENORES PHARMS's Recent FDA Approvals
New NDA/BLA approvals for SENORES PHARMS over the last two years — novel drugs only, excluding generics and label supplements.
SENORES PHARMS's Therapeutic Areas
SENORES PHARMS's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Immunology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
SENORES PHARMS's Top Competitors
SENORES PHARMS's closest competitors by therapeutic-area and drug-target overlap include AstraZeneca, Novartis, and Boehringer Ingelheim. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
SENORES PHARMS Pipeline Snapshot
Active clinical trials for SENORES PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • PRASUGREL leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Discontinued (0)
Company Info
- First Approval
- 1981-06-03
- Latest
- 2026-06-18
- Applications
- 52